Luxembourg

Luxembourg

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.75 (0.62 - 0.88) 2019 Modelled IHME
0.76 (0.62 - 0.88) 2018 Modelled IHME
0.76 (0.62 - 0.89) 2017 Modelled IHME
0.77 (0.64 - 0.90) 2016 Modelled IHME
0.79 (0.65 - 0.92) 2015 Modelled IHME
0.79 (0.66 - 0.93) 2014 Modelled IHME
0.8 (0.66 - 0.94) 2013 Modelled IHME
0.8 (0.66 - 0.95) 2012 Modelled IHME
0.81 (0.66 - 0.96) 2011 Modelled IHME
0.81 (0.66 - 0.97) 2010 Modelled IHME
0.82 (0.66 - 0.98) 2009 Modelled IHME
0.83 (0.67 - 0.99) 2008 Modelled IHME
0.84 (0.68 - 1) 2007 Modelled IHME
0.85 (0.68 - 1.01) 2006 Modelled IHME
0.86 (0.68 - 1.03) 2005 Modelled IHME
0.86 (0.70 - 1.03) 2004 Modelled IHME
0.87 (0.71 - 1.04) 2003 Modelled IHME
0.88 (0.73 - 1.05) 2002 Modelled IHME
0.89 (0.73 - 1.05) 2001 Modelled IHME
0.9 (0.73 - 1.06) 2000 Modelled IHME
0.9 (0.74 - 1.07) 1999 Modelled IHME
0.9 (0.74 - 1.06) 1998 Modelled IHME
0.91 (0.74 - 1.07) 1997 Modelled IHME
0.91 (0.73 - 1.08) 1996 Modelled IHME
0.91 (0.73 - 1.09) 1995 Modelled IHME
0.91 (0.73 - 1.08) 1994 Modelled IHME
0.92 (0.74 - 1.08) 1993 Modelled IHME
0.92 (0.75 - 1.09) 1992 Modelled IHME
0.92 (0.76 - 1.09) 1991 Modelled IHME
0.93 (0.77 - 1.11) 1990 Modelled IHME
0.71 (0.05 - 11.68) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.09 (0.06 - 0.13) 2019 Modelled IHME
0.1 (0.07 - 0.13) 2018 Modelled IHME
0.1 (0.07 - 0.13) 2017 Modelled IHME
0.08 (0.06 - 0.11) 2016 Modelled IHME
0.06 (0.04 - 0.08) 2015 Modelled IHME
0.06 (0.04 - 0.08) 2014 Modelled IHME
0.05 (0.03 - 0.07) 2013 Modelled IHME
0.05 (0.03 - 0.07) 2012 Modelled IHME
0.04 (0.03 - 0.06) 2011 Modelled IHME
0.04 (0.03 - 0.06) 2010 Modelled IHME
0.05 (0.03 - 0.06) 2009 Modelled IHME
0.05 (0.03 - 0.07) 2008 Modelled IHME
0.06 (0.04 - 0.08) 2007 Modelled IHME
0.07 (0.04 - 0.09) 2006 Modelled IHME
0.08 (0.05 - 0.11) 2005 Modelled IHME
0.09 (0.06 - 0.12) 2004 Modelled IHME
0.1 (0.06 - 0.13) 2003 Modelled IHME
0.11 (0.07 - 0.15) 2002 Modelled IHME
0.12 (0.08 - 0.17) 2001 Modelled IHME
0.14 (0.09 - 0.20) 2000 Modelled IHME
0.18 (0.12 - 0.25) 1999 Modelled IHME
0.23 (0.15 - 0.32) 1998 Modelled IHME
0.29 (0.18 - 0.40) 1997 Modelled IHME
0.34 (0.21 - 0.46) 1996 Modelled IHME
0.36 (0.22 - 0.50) 1995 Modelled IHME
0.36 (0.23 - 0.49) 1994 Modelled IHME
0.36 (0.23 - 0.49) 1993 Modelled IHME
0.36 (0.24 - 0.49) 1992 Modelled IHME
0.36 (0.24 - 0.49) 1991 Modelled IHME
0.36 (0.24 - 0.48) 1990 Modelled IHME
0.24 (0.02 - 4.06) 2015 Modelled WHO
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
7 (3.10 - 13.20) 2005 Survey/reported Removille N et al, 2011

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
11 (7 - 16) 2019 Modelled IHME
11 (7 - 16) 2018 Modelled IHME
11 (7 - 16) 2017 Modelled IHME
11 (7 - 16) 2016 Modelled IHME
11 (7 - 16) 2015 Modelled IHME
11 (7 - 16) 2014 Modelled IHME
11 (7 - 16) 2013 Modelled IHME
11 (8 - 16) 2012 Modelled IHME
11 (8 - 16) 2011 Modelled IHME
11 (8 - 16) 2010 Modelled IHME
11 (8 - 16) 2009 Modelled IHME
12 (8 - 17) 2008 Modelled IHME
12 (8 - 17) 2007 Modelled IHME
12 (8 - 18) 2006 Modelled IHME
12 (8 - 18) 2005 Modelled IHME
12 (8 - 18) 2004 Modelled IHME
12 (8 - 18) 2003 Modelled IHME
12 (8 - 18) 2002 Modelled IHME
12 (8 - 18) 2001 Modelled IHME
12 (8 - 17) 2000 Modelled IHME
12 (8 - 18) 1999 Modelled IHME
12 (8 - 18) 1998 Modelled IHME
12 (8 - 18) 1997 Modelled IHME
12 (8 - 18) 1996 Modelled IHME
12 (8 - 18) 1995 Modelled IHME
12 (8 - 18) 1994 Modelled IHME
12 (8 - 18) 1993 Modelled IHME
12 (8 - 18) 1992 Modelled IHME
12 (8 - 17) 1991 Modelled IHME
12 (8 - 17) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
96 2018 Survey/reported WHO/UNICEF
94 2017 Survey/reported WHO/UNICEF
94 2016 Survey/reported WHO/UNICEF
94 2015 Survey/reported WHO/UNICEF
94 2014 Survey/reported WHO/UNICEF
94 2013 Survey/reported WHO/UNICEF
94 2012 Survey/reported WHO/UNICEF
95 2011 Survey/reported WHO/UNICEF
94 2010 Survey/reported WHO/UNICEF
95 2009 Survey/reported WHO/UNICEF
94 2008 Survey/reported WHO/UNICEF
87 2007 Survey/reported WHO/UNICEF
95 2006 Survey/reported WHO/UNICEF
95 2005 Survey/reported WHO/UNICEF
94 2004 Survey/reported WHO/UNICEF
95 2003 Survey/reported WHO/UNICEF
95 2002 Survey/reported WHO/UNICEF
86 2001 Survey/reported WHO/UNICEF
77 2000 Survey/reported WHO/UNICEF
67 1999 Survey/reported WHO/UNICEF
58 1998 Survey/reported WHO/UNICEF
49 1997 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
308 2017 Survey/reported EMCDDA, 2019
165 (137 - 207) 2016 Survey/reported EMCDDA, 2016
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
66 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.84 (0.69 - 1.01) 2019 Modelled IHME
0.83 (0.68 - 1) 2018 Modelled IHME
0.83 (0.68 - 1.01) 2017 Modelled IHME
0.82 (0.67 - 0.99) 2016 Modelled IHME
0.82 (0.67 - 1) 2015 Modelled IHME
0.82 (0.67 - 0.99) 2014 Modelled IHME
0.82 (0.67 - 0.99) 2013 Modelled IHME
0.82 (0.67 - 0.99) 2012 Modelled IHME
0.82 (0.68 - 1) 2011 Modelled IHME
0.82 (0.67 - 1) 2010 Modelled IHME
0.82 (0.68 - 1) 2009 Modelled IHME
0.82 (0.68 - 1) 2008 Modelled IHME
0.82 (0.68 - 1) 2007 Modelled IHME
0.82 (0.68 - 1) 2006 Modelled IHME
0.82 (0.67 - 1) 2005 Modelled IHME
0.82 (0.67 - 1) 2004 Modelled IHME
0.82 (0.67 - 1) 2003 Modelled IHME
0.82 (0.68 - 1) 2002 Modelled IHME
0.82 (0.67 - 0.99) 2001 Modelled IHME
0.82 (0.67 - 0.99) 2000 Modelled IHME
0.82 (0.67 - 0.99) 1999 Modelled IHME
0.82 (0.67 - 0.99) 1998 Modelled IHME
0.82 (0.67 - 0.99) 1997 Modelled IHME
0.82 (0.67 - 0.99) 1996 Modelled IHME
0.81 (0.67 - 0.99) 1995 Modelled IHME
0.81 (0.67 - 0.99) 1994 Modelled IHME
0.81 (0.67 - 0.99) 1993 Modelled IHME
0.81 (0.67 - 0.99) 1992 Modelled IHME
0.81 (0.67 - 1) 1991 Modelled IHME
0.81 (0.67 - 1) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.9 (0.60 - 0.90) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
81.3 (76.20 - 85.80) 2005 Survey/reported Origer A and Schmit J, 2012
Prisoners
Download
Value (%) Year Type Source
86.3 (79 - 91.80) 2005 Survey/reported Removille N et al, 2011

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
40 (30 - 49) 2019 Modelled IHME
40 (30 - 49) 2018 Modelled IHME
40 (30 - 50) 2017 Modelled IHME
40 (30 - 50) 2016 Modelled IHME
40 (30 - 50) 2015 Modelled IHME
39 (29 - 49) 2014 Modelled IHME
39 (29 - 49) 2013 Modelled IHME
39 (29 - 49) 2012 Modelled IHME
39 (29 - 49) 2011 Modelled IHME
39 (30 - 49) 2010 Modelled IHME
39 (29 - 49) 2009 Modelled IHME
39 (29 - 49) 2008 Modelled IHME
39 (29 - 49) 2007 Modelled IHME
38 (29 - 49) 2006 Modelled IHME
38 (29 - 49) 2005 Modelled IHME
38 (29 - 48) 2004 Modelled IHME
38 (29 - 48) 2003 Modelled IHME
38 (29 - 48) 2002 Modelled IHME
38 (29 - 48) 2001 Modelled IHME
38 (28 - 48) 2000 Modelled IHME
38 (28 - 47) 1999 Modelled IHME
37 (28 - 47) 1998 Modelled IHME
37 (28 - 47) 1997 Modelled IHME
37 (28 - 47) 1996 Modelled IHME
37 (28 - 47) 1995 Modelled IHME
37 (27 - 47) 1994 Modelled IHME
37 (27 - 47) 1993 Modelled IHME
37 (27 - 47) 1992 Modelled IHME
37 (27 - 47) 1991 Modelled IHME
37 (27 - 47) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 2017 Survey/reported EMCDDA, 2019
165 (137 - 207) 2016 Survey/reported EMCDDA, 2016
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
66 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.75 (%)
2019
(0.62 - 0.88(%))
IHME
HCV (RNA/cAg+)
0.84 (%)
2019
(0.69 - 1.01(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
10
2019
(7 - 13)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
30
2019
(23 - 38)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.09 (%)
2019, latest modelled
(0.06 - 0.13(%))
IHME

Prevalence PWID

HCV
0
, latest modelled

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
308
2017
EMCDDA, 2019
Eligible for HBV generic medicines
Eligible for HCV generic medicines